You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Assessment of antihistamines in the treatment of skin allergies

Murota, Hiroyuki; Katayama, Ichiro

Current Opinion in Allergy & Clinical Immunology:
doi: 10.1097/ACI.0b013e32834a96e9
Skin allergy: Edited by Torsten Zuberbier and Thomas Werfel
Abstract

Purpose of review: Antihistamines, both old first-generation and new, are frequently prescribed to patients with allergic skin diseases. As the expected roles of antihistamines differ in each dermatosis, we should carefully consider the characteristics of each antihistamine prior to use. This review covers recent antihistamine topics, including novel pharmacological action, and enhancement of patient quality of life (QoL).

Recent findings: Nonsedative, second-generation antihistamines are recommended as first-line treatment for urticaria. For atopic dermatitis, most position papers doubt their efficacy of treatment due to insufficient evidence. However, recent articles revealed novel H1 receptor-independent properties for these agents, such as modulation of cytokine and chemokine production, tissue remodeling, and indicated its favorable effects on atopic dermatitis. Furthermore, several important benefits of second-generation antihistamines on the amelioration of atopic dermatitis symptoms, patient QoL and labor efficiency including loss of productivity and absenteeism from the workplace have been reported. In contrast, prescription of first-generation antihistamines for skin allergies should be avoided due to their bad risk/benefit ratio. Whereas they are not better in controlling itch, they also fail to improve patient labor efficiency unlike second-generation antihistamines.

Summary: Although antihistamine usefulness varies greatly, understanding the characteristics of each antihistamine will allow more personalized therapy for skin allergies.

Author Information

Course of Integrated Medicine, Department of Dermatology, Graduate School of Medicine, Osaka University, Osaka, Japan

Correspondence to Hiroyuki Murota, MD, PhD, 2-2 Yamadaoka, Suita, Osaka 5650871, JapanTel: +81 668793031; fax: +81 668793039; e-mail: h-murota@derma.med.osaka-u.ac.jp

Copyright © 2011 Wolters Kluwer Health, Inc. All rights reserved.